| 1.03 0.02 (1.98%) | 04-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.42 | 1-year : | 1.57 |
| Resists | First : | 1.22 | Second : | 1.35 |
| Pivot price | 1.16  |
|||
| Supports | First : | 1 | Second : | 0.84 |
| MAs | MA(5) : | 1.07 |
MA(20) : | 1.15 |
| MA(100) : | 1.27 |
MA(250) : | 1.66 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 4.2 |
D(3) : | 6.3 |
| RSI | RSI(14): 36.1  |
|||
| 52-week | High : | 4.36 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MBOT ] has closed above bottom band by 10.2%. Bollinger Bands are 15.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.1 - 1.11 | 1.11 - 1.12 |
| Low: | 0.99 - 1 | 1 - 1.01 |
| Close: | 1.02 - 1.03 | 1.03 - 1.04 |
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company, through its ViRob, TipCAT, CardioSert, and Liberty micro-robotic technologies, developing Self Cleaning Shunt for the treatment of hydrocephalus and normal pressure hydrocephalus; a disposable robot for various endovascular interventional procedures; and a multi generation pipeline portfolio. It has 42 issued/allowed patents and 23 patent applications pending worldwide. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts.
Mon, 15 Apr 2024
Microbot Medical maintains progress amid Israel tensions By Investing.com - Investing.com UK
Mon, 15 Apr 2024
Microbot Medical Shares Status Following Recent Geopolitical Events - Yahoo Finance
Fri, 12 Apr 2024
Microbot Medical Inc. (NASDAQ:MBOT) Short Interest Update - Defense World
Tue, 09 Apr 2024
Alpha Tau Medical (NASDAQ:DRTS) and Microbot Medical (NASDAQ:MBOT) Critical Review - Defense World
Mon, 01 Apr 2024
Do Traders Think Microbot Medical Inc (MBOT) Can Keep Climbing Monday? - InvestorsObserver
Tue, 20 Feb 2024
Microbot Medical Inc (NASDAQ:MBOT): A Fully Funded Medical Device Punt - Insider Financial
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 14 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 12.2 (%) |
| Shares Short | 173 (K) |
| Shares Short P.Month | 22 (K) |
| EPS | -1.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -69 % |
| Return on Equity (ttm) | -182.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.99 |
| PEG Ratio | 0 |
| Price to Book value | 2.71 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|